C-Further, an international consortium that funds pursuit of new treatments for cancers impacting children and young people, has announced support for Dr. John Bushweller’s work to develop a first-in-class ETV6 inhibitor to “address an urgent unmet need in relapsed and metastatic Ewing sarcoma.” C-Further was established in 2024 to advance innovations for children and young people’s cancers, funded by Cancer Research UK, one of the largest non-profit investors in cancer research, and LifeArc, a medical charity that seeks new treatments for underserved diseases, with a current budget of $40 million. Dr. Bushweller, a faculty member of the Center for Membrane and Cell Physiology, appeared on NBC29 to discuss the project, which will be conducted in partnership with Dana-Farber Cancer Institute and Mass General Brigham. He emphasized the importance of philanthropic support for research targeting rare cancers.
| NBC29 coverage |
| C-Forward announcement |